Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Isocitrate lyase Icl (isocitrase) (isocitratase) | 0.3918 | 1 | 1 |
Echinococcus multilocularis | arachidonate 5 lipoxygenase | 0.0061 | 0.01 | 0.9426 |
Schistosoma mansoni | 3-hydroxyacyl-CoA dehydrogenase | 0.0063 | 0.0106 | 1 |
Leishmania major | 3-oxoacyl-(acyl-carrier protein) reductase, putative | 0.0063 | 0.0106 | 0.5 |
Brugia malayi | 3-hydroxyacyl-CoA dehydrogenase type II | 0.0063 | 0.0106 | 1 |
Onchocerca volvulus | 0.0022 | 0 | 0.5 | |
Echinococcus granulosus | arachidonate 5 lipoxygenase | 0.0061 | 0.01 | 0.9426 |
Plasmodium falciparum | LCCL domain-containing protein | 0.0022 | 0 | 0.5 |
Mycobacterium ulcerans | isocitrate lyase AceAb | 0.3918 | 1 | 1 |
Loa Loa (eye worm) | 3-hydroxyacyl-CoA dehydrogenase type II | 0.0059 | 0.0095 | 1 |
Onchocerca volvulus | 0.0022 | 0 | 0.5 | |
Plasmodium vivax | multidomain scavenger receptor, putative | 0.0022 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable isocitrate lyase AceAb [second part] (isocitrase) (isocitratase) (Icl) | 0.3918 | 1 | 1 |
Mycobacterium tuberculosis | Probable isocitrate lyase AceAa [first part] (isocitrase) (isocitratase) (Icl) | 0.3918 | 1 | 1 |
Echinococcus multilocularis | 3 hydroxyacyl coenzyme A dehydrogenase type 2 | 0.0063 | 0.0106 | 1 |
Schistosoma mansoni | lipoxygenase | 0.0061 | 0.01 | 0.9426 |
Echinococcus granulosus | 3 hydroxyacyl coenzyme A dehydrogenase type 2 | 0.0063 | 0.0106 | 1 |
Mycobacterium ulcerans | isocitrate lyase Icl | 0.3918 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (ADMET) | = 2400 uM | Cytotoxicity against human PBMC by XTT assay | ChEMBL. | 19581097 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.